SCHEMBL6222829

SCHEMBL6222829

CCOC(=O)c1ccc(OC(C)C2CCNCC2)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
ALDH1A1 P00352 4/20 0.56
MAPK1 P28482 1/20 0.56
HSD17B2 P37059 1/20 0.51
LMNA P02545 2/20 0.48
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 1/20 0.45
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469675 0.84 CA12 (0.55) MAPK1LMNARAB9ATSHRHTT
SCHEMBL6166429 0.84 MAPT (0.48) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL7684319 0.83 MAPT (0.77) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL27574703 0.81 CA12 (0.45) MAPTLMNARAB9ANPC1HTT
SCHEMBL6168127 0.80 KDM4E (0.45) MAPTALDH1A1MAPK1TSHRALOX15
SCHEMBL11341115 0.79 MAPT (0.61) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL30506315 0.77 HSD17B2 (0.76) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL1660365 0.77 HSD17B2 (0.76) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL6166515 0.77 MAPT (0.49) MAPTALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL6638697 0.74 SLC6A2 (0.44) MAPTALDH1A1MAPK1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592423-A2 COMBINATION THERAPY OF ZD6474 WITH 5-FU AND/OR CPT-11 Astrazeneca AB (SE) 2005-11-09 EP disclosed
EP-1534287-A1 COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER Astrazeneca AB (SE) 2005-06-01 EP disclosed
WO-2004071397-A2 COMBINATION THERAPY OF ZD6474 WITH 5-FU OR/AND CPT-11 ASTRAZENECA AB (SE) 2004-08-26 WO disclosed
EP-1446124-A1 COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE AstraZeneca AB (SE) 2004-08-18 EP disclosed
WO-2004014383-A1 COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-02-19 WO disclosed
WO-2003039551-A1 COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE ASTRAZENECA AB (SE) 2003-05-15 WO disclosed
EP-1244647-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS AstraZeneca AB (SE) 2002-10-02 EP disclosed
EP-1218355-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2002-07-03 EP disclosed
EP-1218354-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2002-07-03 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 EP disclosed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 WO disclosed
WO-2001021597-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-03-29 WO disclosed
WO-2001021596-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2001-03-29 WO disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 WO disclosed